CBIO Projected Dividend Yield

Catalyst Biosciences Inc ( NASDAQ : CBIO )

Catalyst Biosciences, together with its subsidiary, is a biopharmaceutical company focused on development and commercialization of Hydronidone for the treatment of NASH (nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease) in the U.S. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the U.S. and generated pharmacokinetic, safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects.

12 YEAR PERFORMANCE RESULTS